Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF).
Greillier L, Gauvrit M, Paillaud E, Girard N, Montégut C, Boulahssass R, Wislez M, Pamoukdjian F, Corre R, Cabart M, Caillet P, Belaroussi Y, Frasca M, Noize P, Wang P, Mebarki S, Mathoulin-Pelissier S, Couderc AL. Greillier L, et al. Among authors: wislez m. Cancers (Basel). 2022 Feb 2;14(3):769. doi: 10.3390/cancers14030769. Cancers (Basel). 2022. PMID: 35159036 Free PMC article. Review.
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C. Auliac JB, et al. Among authors: wislez m. Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27. Lung Cancer. 2019. PMID: 30642559
Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?
Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B. Bellesoeur A, et al. Among authors: wislez m. Cancers (Basel). 2019 Nov 13;11(11):1784. doi: 10.3390/cancers11111784. Cancers (Basel). 2019. PMID: 31766292 Free PMC article.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Among authors: wislez m. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.
Girard N, Greillier L, Zalcman G, Cadranel J, Moro-Sibilot D, Mazières J, Audigier-Valette C, Bennouna J, Besse B, Cortot A, Couraud S, Duruisseaux M, Giroux-Leprieur E, Toffart AC, Westeel V, Wislez M; French-Language Society of Pulmonology SPLF French-language Oncology Group. Girard N, et al. Among authors: wislez m. Respir Med Res. 2020 Nov;78:100769. doi: 10.1016/j.resmer.2020.100769. Epub 2020 May 24. Respir Med Res. 2020. PMID: 32563968 Free PMC article.
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, Wislez M, Trédaniel J, Spano JP, Helissey C, Chouaid C, Molinier O, Dhalluin X, Doucet L, Hureaux J, Cazes A, Zalcman G. Gounant V, et al. Among authors: wislez m. Cancers (Basel). 2021 Mar 2;13(5):1040. doi: 10.3390/cancers13051040. Cancers (Basel). 2021. PMID: 33801285 Free PMC article.
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Wislez M, Domblides C, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano JP, Ricordel C, Fraisse P, Janicot H, Audigier-Valette C, Amour E, Langlais A, Rabbe N, Makinson A, Cadranel J, Laurent-Puig P, Lavolé A, Blons H. Wislez M, et al. Lung Cancer. 2021 Jul;157:124-130. doi: 10.1016/j.lungcan.2021.05.013. Epub 2021 May 13. Lung Cancer. 2021. PMID: 34016488 Clinical Trial.
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy.
Chelabi S, Mignard X, Leroy K, Monnet I, Brosseau S, Theou-Anton N, Massiani MA, Friard S, Duchemann B, Fabre E, Giroux-Leprieur E, Cadranel J, Wislez M. Chelabi S, et al. Among authors: wislez m. Cancers (Basel). 2021 Oct 13;13(20):5132. doi: 10.3390/cancers13205132. Cancers (Basel). 2021. PMID: 34680280 Free PMC article.
Updated Prognostic Factors in Localized NSCLC.
Garinet S, Wang P, Mansuet-Lupo A, Fournel L, Wislez M, Blons H. Garinet S, et al. Among authors: wislez m. Cancers (Basel). 2022 Mar 9;14(6):1400. doi: 10.3390/cancers14061400. Cancers (Basel). 2022. PMID: 35326552 Free PMC article. Review.
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.
Assié JB, Crépin F, Grolleau E, Canellas A, Geier M, Grébert-Manuardi A, Akkache N, Renault A, Hauss PA, Sabatini M, Bonnefoy V, Cortot A, Wislez M, Gauvain C, Chouaïd C, Scherpereel A, Monnet I. Assié JB, et al. Among authors: wislez m. Cancers (Basel). 2022 Mar 15;14(6):1498. doi: 10.3390/cancers14061498. Cancers (Basel). 2022. PMID: 35326648 Free PMC article.
265 results